KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Operating Expenses (2017 - 2025)

Teva Pharmaceutical Industries' Other Operating Expenses history spans 9 years, with the latest figure at -$3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 62.5% year-over-year to -$3.0 million, compared with a TTM value of -$19.0 million through Dec 2025, down 235.71%, and an annual FY2025 reading of -$18.0 million, down 228.57% over the prior year.
  • Other Operating Expenses for Q4 2025 was -$3.0 million at Teva Pharmaceutical Industries, up from -$7.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $52.0 million in Q1 2022, with the low at -$8.0 million in Q4 2024.
  • Average Other Operating Expenses over 5 years is $12.5 million, with a median of $5.5 million recorded in 2021.
  • Year-over-year, Other Operating Expenses skyrocketed 940.0% in 2022 and then plummeted 400.0% in 2025.
  • Tracing TEVA's Other Operating Expenses over 5 years: stood at $25.0 million in 2021, then fell by 24.0% to $19.0 million in 2022, then plummeted by 68.42% to $6.0 million in 2023, then tumbled by 233.33% to -$8.0 million in 2024, then soared by 62.5% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Other Operating Expenses are -$3.0 million (Q4 2025), -$7.0 million (Q3 2025), and -$4.0 million (Q2 2025).